Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2023 | $8.00 | Equal-Weight | Morgan Stanley |
| 3/16/2023 | $17.00 | Buy | Needham |
| 9/16/2022 | $20.00 | Overweight | KeyBanc Capital Markets |
| 4/18/2022 | $10.00 | Buy → Neutral | BofA Securities |
| 3/4/2022 | $32.00 → $10.00 | Outperform → Market Perform | SVB Leerink |
| 12/8/2021 | $30.00 → $32.00 | Outperform | SVB Leerink |
| 9/21/2021 | $37.00 | Buy | Berenberg |
| 8/16/2021 | $33.00 → $30.00 | Outperform | SVB Leerink |
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday. Shares of The Bank of New York Mellon Corporation (NYSE:BK) rose during Friday's session following better-than-expected quarterly financial results. The finance behemoth reported second-quarter adjusted earnings per share of $1.51, beating the street view of $1.43. Quarterly revenue of $4.597 billion, an increase of 2% year-over-year, surpassed the analyst consensus of $4.523 billion, according to data from Benzinga Pro. Bank of New York Mellon shares surged 4.3% to $64.12 on Friday. Here are some other big stocks recording gains in today’s session. Lucid Group, Inc. (NASDAQ:LCID) sh
Keybanc analyst Scott Schoenhaus maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $16 to $12.
On Tuesday, Cathie Wood-led Ark Invest made significant adjustments to its portfolio, offloading a substantial number of shares in Tesla Inc (NASDAQ:TSLA) and scooping up a hefty stake in Palantir Technologies Inc (NYSE:PLTR). The Tesla Trade Ark Invest reduced its stake in Tesla across two of its ETFs — ARK Innovation ETF (NYSE:ARKK) and ARK Next Generation Internet ETF (NYSE:ARKW). The firm sold 56,425 and 6,442 shares respectively, the transaction was valued at $14.54 million. On Tuesday, Tesla shares closed 10.2% higher at $231.26, driven higher by the second-quarter delivery report of the company. The numbers came ahead of the consensus estimate. This move comes despite Wood’s
Morgan Stanley initiated coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $8.00
Needham initiated coverage of Recursion Pharmaceuticals with a rating of Buy and set a new price target of $17.00
KeyBanc Capital Markets initiated coverage of Recursion Pharmaceuticals with a rating of Overweight and set a new price target of $20.00
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
S-8 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
Salt Lake City, UT, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its Q3 2024 financial results on Wednesday, Nov 6, 2024, following the close of the financial markets. The company will not host its normal L(earnings) Call in relation to the business updates and financials for the third quarter. Instead, the company expects to host an update call after the anticipated close of the proposed business combination with Exscientia, which is expected to be on Nov 20, 2024. We will broadcast the live stream from Recursion's X (formerl
Salt Lake City, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, following the close of the financial markets. Recursion will host a L(earnings) Call on August 8, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time, interacting with a broad public audience around notable business developments and offering opportunities to ask questions. Recursion will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn and YouTube accounts. This event is free, open t
SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its first quarter 2024 financial results on Thursday, May 9, 2024, following the close of the financial markets. Additionally, Recursion will host its quarterly L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time. A L(earnings) Call is Recursion's take on interacting with a broad public audience around notable business developments and offering opportunities to ask questions. Recursion will broadcast the live stream from Recursion's X (for
Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methodsHighly complementary pipeline with approximately 10 clinical readouts expected over the next 18 monthsIndustry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone
SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of Recursion, effective at the end of this term, as Martin Chavez exits after more than four years of leadership. "I'm excited to bring my clinical and scientific expertise to support Recursion's growth as Chair of the Board," said Dr. Hershberg. "In my opinion, the intersection of scientific rigor and technology to drive novel programs is the future of drug discovery and I believe Recursion will be a leader in this emerging sp
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will lead Recursion's research and development, and build its emerging commercial capabilities. She has also been appointed to Recursion's Board of Directors. "Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business," said Chris Gibson, Co-Founder and CEO of Recursion. "More importantly, she has a vision and passion for transforming drug disco
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discoveryRecursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT on LinkedIn, X and Youtube SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (NASDAQ:RXRX) and Exscientia has been completed, wi
Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) and Exscientia plc (NASDAQ:EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia. The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update call after the anticipated close on November 20, 2024 at 7:30 a.m. ET / 5:30 a.m MT / 12:30 p.m. GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn and YouTube accounts. Questions can be submitted via this link ahead of
SALT LAKE CITY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today the release of OpenPhenom-S/16, a publicly available foundation model in Google Cloud's Vertex AI Model Garden. This will enable Life Science companies to use OpenPhenom-S/16 on Google Cloud when building apps that require microscopy data to assess the effectiveness of drug treatments, analyze cultures, study tissues and ultimately accelerate drug discovery and for other uses. "We are thrilled to announce that Recursion is setting a new gold standard for the industry with the release of OpenPhenom-S/16, a foun